登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：301331 证券简称：恩威医药 公告编号：2025-044 1、本次解除限售并上市流通的限售股份为恩威医药股份有限公司（以下简称"公司"）首次公开发行前 限售股； 2、本次解除限售股东户数共计5户，解除限售的股份数量为69,790,184股，占公司总股本的67.83%；限 售期为自公司首次公开发行股票并上市之日起36个月； 3、本次解除限售股份的上市流通日期为2025年9月25日（星期四）。 4、根据公司2025年1月21日披露的《关于控股股东一致行动人取得金融机构增持贷款承诺暨增持公司股 份计划的公告》（公告编号：2025-002），以及2025年7月18日披露的《关于控股股东一致行动人增持 公司股份计划实施完毕暨增持结果的公告》（公告编号：2025-031），成都杰威企业管理有限公司（以 下简称"成都杰威"）及其一致行动人承诺：在增持计划实施期间及增持计划完成后六个月内不减持其所 持有的公司股份，即2025年7月18日至2026年1月17日期间，成都杰威及其一致行动人成都恩威投资（集 团）有限公司（以下简称"恩威集团"）、成都瑞进恒企业管理有限 ...

证券日报网讯9月22日晚间，恩威医药（301331）发布关于首次公开发行前已发行股份部分解除限售并 上市流通的提示性公告称，本次解除限售并上市流通的限售股份为公司首次公开发行前限售股；本次解 除限售股东户数共计5户，解除限售的股份数量为69，790，184股，占公司总股本的67.83%；限售期为 自公司首次公开发行股票并上市之日起36个月；本次解除限售股份的上市流通日期为2025年9月25日(星 期四)。 ...

证券代码：301331 证券简称：恩威医药 公告编号：2025-044 恩威医药股份有限公司 关于首次公开发行前已发行股份部分解除限售并上市流通 的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售并上市流通的限售股份为恩威医药股份有限公司（以下简 称"公司"）首次公开发行前限售股； 2、本次解除限售股东户数共计5户，解除限售的股份数量为69,790,184股， 占公司总股本的67.83%；限售期为自公司首次公开发行股票并上市之日起36个月； 3、本次解除限售股份的上市流通日期为2025年9月25日（星期四）。 4、根据公司2025年1月21日披露的《关于控股股东一致行动人取得金融机构 增持贷款承诺暨增持公司股份计划的公告》（公告编号：2025-002），以及2025 年7月18日披露的《关于控股股东一致行动人增持公司股份计划实施完毕暨增持 结果的公告》（公告编号：2025-031），成都杰威企业管理有限公司（以下简称 "成都杰威"）及其一致行动人承诺：在增持计划实施期间及增持计划完成后六 个月内不减持其所持有的公司股份， ...

中信证券股份有限公司 关于恩威医药股份有限公司首次公开发行前 已发行股份部分解除限售并上市流通的核查意见 二、申请解除股份限售股东的相关承诺及履行情况 中信证券股份有限公司（以下简称"中信证券"或"保荐机构"）担任恩威 医药股份有限公司（以下简称"恩威医药"、"上市公司"或"公司"）首次公开 发行股票并在创业板上市持续督导阶段的保荐机构，根据《证券发行上市保荐业 务管理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司 自律监管指引第 13 号——保荐业务》以及《深圳证券交易所上市公司自律监管 指引第 2 号——创业板上市公司规范运作》等有关规定，对恩威医药首次公开发 行前已发行股份部分解除限售并上市流通的事项进行了审慎核查，并出具本核查 意见如下： 一、首次公开发行前已发行股份概况 经中国证券监督管理委员会《关于同意恩威医药股份有限公司首次公开发行 股票注册的批复》（证监许可[2022]1786 号）同意注册，并经深圳证券交易所同 意，公司首次向社会公开发行人民币普通股（A 股）股票 17,540,000 股，并于 2022 年 9 月 21 日在深圳证券交易所创业板挂牌上市。 公司首次公开 ...

Group 1 - A total of 51 stocks will face unlock next week, with a combined market value of 61.922 billion yuan based on the latest closing prices [9][11] - The largest unlock value will be from Hehe Information, with 69 million shares becoming tradable, amounting to 10.835 billion yuan [9] - Ziyan Food will also see a significant unlock, with 344 million shares and an unlock value of 7.126 billion yuan [9] Group 2 - Stocks facing unlock have seen an average price decline of 0.53% since September [11] - Among the stocks, Xizhuang Co., *ST Yuanshang, and Heshun Technology have experienced price increases of over 20% in September [11] - Xizhuang Co. leads with a price increase of 39.06% and will have 81 million shares unlocking, valued at 4.239 billion yuan [11] Group 3 - Ziyan Food has the largest price drop among the stocks, with a decline of 20.46% in September, coinciding with its unlock of 344 million shares valued at 7.126 billion yuan [12] - Several companies, including Jiaotong Iron and Ice Wheel Environment, have recently received institutional research, indicating potential interest from investors [12] - Generally, the negative impact of unlocks is more pronounced for underperforming stocks compared to those with strong performance [12] Group 4 - Specific stocks facing significant unlocks include Hehe Information, Ziyan Food, and Wireless Media, with respective unlock values of 10.835 billion yuan, 7.126 billion yuan, and 5.521 billion yuan [13] - The unlock ratios for Ziyan Food, Xizhuang Co., and Enwei Pharmaceutical exceed 50%, indicating a substantial portion of their shares will be available for trading [9]

■ 一、保荐工作概述 ■ 二、保荐人发现公司存在的问题及采取的措施 ■ 三、公司及股东承诺事项履行情况 ■ 四、其他事项 ■ 保荐代表人： 石 坡 叶建中 中信证券股份有限公司 2025年 9 月 15 日 ...

中信证券股份有限公司 | （1）列席公司股东大会次数 | 未亲自列席，已审阅历次会议文件 | | --- | --- | | （2）列席公司董事会次数 | 未亲自列席，已审阅历次会议文件 | | （3）列席公司监事会次数 | 未亲自列席，已审阅历次会议文件 | | 5.现场检查情况 | | | （1）现场检查次数 | 1次，对募集资金进行核查 | | （2）现场检查报告是否按照深圳证券交易所规定 | 不适用 | | 报送 | | | （3）现场检查发现的主要问题及整改情况 | 不适用 | | 6.发表专项意见情况 | | | （1）发表专项意见次数 | 4次 | | （2）发表非同意意见所涉问题及结论意见 | 无 | | 7.向深圳证券交易所报告情况（现场检查报告除 | | | 外） | | | （1）向深圳证券交易所报告的次数 | 0次 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8.关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 无 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情况 | ...

Core Viewpoint - Enwei Pharmaceutical reported significant growth in its operating performance for the first half of 2025, driven by the market impact of key products from Henan Xinxin Pharmaceutical, online sales growth, and a substantial reduction in amortization expenses [1][2]. Financial Performance - In the first half of 2025, Enwei Pharmaceutical achieved operating revenue of 449 million yuan, a year-on-year increase of 15.73% - The net profit attributable to shareholders reached 38.34 million yuan, up 113.8% year-on-year - The net profit attributable to shareholders after deducting non-recurring gains and losses was 35.28 million yuan, reflecting a year-on-year growth of 132.47% [1]. Product Development and Market Position - Enwei Pharmaceutical's gynecological products generated operating revenue of 208 million yuan, marking an 11.73% increase year-on-year - The core product "Jie'er Yin Wash" continues to hold the top market share in the gynecological traditional Chinese medicine sector in urban retail pharmacies [2]. - The company has acquired production licenses for 125 varieties through its participation in the bankruptcy reorganization of Henan Xinxin Pharmaceutical, significantly enriching its product pipeline [2]. Strategic Plans - The company aims to develop 8 to 10 products with over 100 million yuan in sales over the next three years to ensure sustainable long-term growth - Enwei Pharmaceutical is actively promoting this cultivation plan by mobilizing resources to accelerate product development [2]. - For the second half of 2025, the company plans to focus on daily operations, marketing efforts, and the revival of key products from Henan Xinxin Pharmaceutical, with a goal of launching around 20 key products by year-end [3].

Core Viewpoint - Enwei Pharmaceutical reported significant growth in its performance for the first half of 2025, driven by the resumption of key products from Henan Xinxin Pharmaceutical and strong online sales, particularly in non-pharmaceutical products [1] Financial Performance - In the first half of 2025, Enwei Pharmaceutical achieved a net profit of 38.34 million yuan, an increase of 113.80% year-on-year [1] - The company's revenue for the same period was 449 million yuan, representing a 15.73% increase compared to the previous year [1] Business Strategy - The company plans to focus on daily operations and production to meet market demand, aiming to launch approximately 20 key products from Henan Xinxin Pharmaceutical by the end of the year [1] - Enwei Pharmaceutical is also looking to expand through mergers and acquisitions, having identified several potential targets since 2024 [1] Product Development - The company aims to develop 8 to 10 product groups with over 100 million yuan in sales within three years starting from 2025 [1] - Current research projects include innovative traditional Chinese medicine and chemical generics, such as nitrofurantoin and elagolix sodium tablets [1] Market Positioning - The acquisition of Henan Xinxin Pharmaceutical is seen as a strategic move to enhance operational efficiency and focus on the traditional Chinese medicine industry chain, which is expected to improve investor recognition and market value [1] Cost Management - The amortization of stock incentive expenses is projected to impact profits by approximately 10 million yuan in 2025 and 3.6 million yuan in 2026 [1]

Financial Performance - In the first half of 2025, the company achieved a net profit of 38.34 million yuan, representing a year-on-year increase of 113.80% [2] - Revenue for the same period reached 449 million yuan, an increase of 15.73% compared to the previous year [4] - The significant profit growth is attributed to the resumption of key products from Henan Xinxin Pharmaceutical, rapid growth in online sales channels, and a substantial reduction in amortization expenses [2][3] Strategic Focus - The company plans to focus on several key areas in the second half of 2025, including: - Strengthening daily operations and marketing efforts to meet market demand [3] - Implementing the development plan for key products from Henan Xinxin Pharmaceutical, aiming to launch approximately 20 key products by year-end [3] - Progressing the construction of the Sichuan pharmaceutical investment project while ensuring compliance and quality [3] - Actively seeking merger and acquisition opportunities [3] Product Development - The company aims to cultivate 8 to 10 billion-level product groups over the next three years to ensure sustainable long-term development [3] - Current research and development projects include innovative traditional Chinese medicine and chemical generic drugs, with specific products in progress [4] Market Expansion - The acquisition of Henan Xinxin Pharmaceutical is a strategic move to expand the product matrix and market coverage, enhancing overall performance [4] - The contribution of Henan Xinxin's new products to revenue and profit is currently minimal, but significant growth is expected with the upcoming batch launches [4] Shareholder Information - As of now, there is no information regarding the major shareholder's intention to reduce their holdings following the full circulation of shares [5] - The estimated impact of stock incentive expense amortization on profits for 2025 and 2026 is approximately 1 million yuan and 360 thousand yuan, respectively [5]